Weight Loss Drugs Could Bankrupt US Healthcare, Senate Report Warns

Citing company “greed,” Sen. Bernie Sanders (I-Vt.) has again blasted Danish pharma Novo Nordisk for the prices of Wegovy and Ozempic, releasing a Senate committee report claiming the popular weight loss and diabetes drugs could bankrupt the US healthcare system.

The report comes less than two months after Sanders — Chairman of the Senate Health, Education, Labor and Pensions (HELP) Committee — ripped the company after a JAMA Network Open article cited that Medicare spending on Ozempic alone reached $4.6 billion in 2022.

The report from the HELP Committee under Sanders’ chairmanship continues its track record of comparing US drug prices to those in other countries. A February Committee hearing grilled Merck CEO Robert Davis, who blamed rebates big pharma must offer to pharmacy benefit managers, a charge rebuffed by the Committee.

To read the whole story, click here.

Related Topics